IP Library Patent Application 18160878
Patent Application
App. No. 18/160,878

ORAL COMPOSITION OF CELECOXIB FOR TREATMENT OF PAIN

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/160,878
Abstract

The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.

Claims (24)

1 . A method for providing pain freedom in a human subject suffering from pain, said method comprising administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib and at least one medium chain glyceride, wherein said composition leads to freedom from pain at 2 hours following administration.

2 . (canceled)

3 . The method of claim 1 , wherein said pain freedom is at least about 10% greater in comparison to the percentage of human subjects being treated with commercially available treatment like VIOXX 25 (25 mg).

4 . The method of claim 1 , wherein said pain freedom is at least about 10% greater in comparison to the percentage of human subjects being treated with commercially available treatment like VIOXX 50 (50 mg).

5 . The method of claim 1 , wherein said pain freedom is at least about 10% greater in comparison to the percentage of human subjects being treated with commercially available treatment like CAMBIA 50 (50 mg).

6 . The method of claim 1 , wherein said pain freedom is maintained for at least about 2 hours to about 24 hours.

7 . The method of claim 1 , wherein said pain is acute pain, migraine pain, cluster headache, neuropathic pain, post-operative pain, chronic lower back pain, herpes neuralgia pain, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain resulting from burns, sunburn pain, post-partum pain, angina pain, genitourinary tract-related pain, cystitis pain, arthritis pain, inflammation pain, osteoarthritis pain, juvenile rheumatoid arthritis pain, ankylosing spondylitis pain, primary dysmenorrhea pain, breakthrough pain, or any kind of cancer pain.

8 . The method of claim 1 , wherein said therapeutically effective amount of celecoxib is about 80 mg to about 300 mg.

9 . The method of claim 1 , wherein said therapeutically effective amount of celecoxib is about 120 mg to about 240 mg.

10 . The method of claim 1 , wherein said composition further comprises at least one solubilizer.

11 . The method of claim 1 , wherein said composition further comprises at least one polar solvent.

12 . (canceled)

13 . A method for providing partial pain relief in a human subject suffering from pain, said method comprising administering to the subject a stable oral liquid pharmaceutical composition comprising a therapeutically effective amount of celecoxib and at least one medium chain glyceride, wherein said composition leads to partial pain relief less than 2 hours following administration.

14 . (canceled)

15 . The method of claim 13 , wherein said partial pain relief is at least about 10% greater in comparison to the percentage of human subjects being treated with commercially available treatment like VIOXX 25 (25 mg).

16 . The method of claim 13 , wherein said partial pain relief is at least about 10% greater in comparison to the percentage of human subjects being treated with commercially available treatment like VIOXX 50 (50 mg).

17 . The method of claim 13 , wherein said partial pain relief is at least about 10% greater in comparison to the percentage of human subjects being treated with commercially available treatment like CAMBIA 50 (50 mg).

18 . The method of claim 13 , wherein said partial pain relief is maintained for at least about 4 hours.

19 . The method of claim 13 , wherein said pain is acute pain, migraine pain, cluster headache, neuropathic pain, post-operative pain, chronic lower back pain, herpes neuralgia pain, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain resulting from burns, sunburn pain, post-partum pain, angina pain, genitourinary tract-related pain, cystitis pain, arthritis pain, inflammation pain, osteoarthritis pain, juvenile rheumatoid arthritis pain, ankylosing spondylitis pain, primary dysmenorrhea pain, breakthrough pain, or any kind of cancer pain.

20 . The method of claim 13 , wherein said therapeutically effective amount of celecoxib is about 80 mg to about 300 mg.

21 . The method of claim 13 , wherein said therapeutically effective amount of celecoxib is about 120 mg to about 240 mg.

22 . The method of claim 13 , wherein said composition further comprises at least one solubilizer.

23 . The method of claim 13 , wherein said composition further comprises at least one polar solvent.

24 . (canceled)

Assignments (4)
SECURITY INTEREST Recorded Sep 21, 2023
From: SCILEX HOLDING COMPANY; SCILEX PHARMACEUTICALS INC.; SEMNUR PHARMACEUTICALS, INC.
To: ACQUIOM AGENCY SERVICES LLC, AS AGENT
Reel/Frame 064987/0939 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2023
From: BIODELIVERY SCIENCES INTERNATIONAL, INC.
To: SCILEX HOLDING COMPANY
Reel/Frame 064912/0951 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2023
From: MUNJAL, SAGAR; BAHETI, ANKIT; PADHI, BIJAY KUMAR; VAKADA, SUPRITHA; RAGHUVANSHI, RAJEEV SINGH
To: DR. REDDY'S LABORATORIES LTD.
Reel/Frame 062517/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2023
From: DR. REDDY'S LABORATORIES LTD.
To: BIODELIVERY SCIENCES INTERNATIONAL, INC.
Reel/Frame 062517/0937 →